You are about to access www.ascendispharma.us. The information on this website is intended for residents of the United States. Click below to confirm you are a citizen and/or resident of the United States.

Committed to Making a Difference in Patients’ Lives

Ascendis Pharma is applying our innovative TransConTM technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we utilize our technology platform to create new and potentially best-in-class therapies. We currently have a pipeline of three independent, endocrinology rare disease product candidates in clinical development, and multiple preclinical programs in oncology, our second therapeutic area.

 

ACcomplisH Now Initiated

ACcomplisH is a global phase 2 clinical trial designed to evaluate TransCon CNP in children with achondroplasia (ACH). Learn More

TransCon Technology Platform

Learn how we’re using our innovative TransCon technology (refers to “transient conjugation”) to create best-in-class products to address unmet patient needs.
Watch Video